Quanterix Corporation (QTRX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test
Quanterix NASDAQ: QTRX CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma markets.
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript
Quanterix Q2 Earnings Call Highlights
Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.
Quanterix: Trading Below 1x Sales Despite A Changing Story
Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base for recurring revenue. The Alzheimer's blood test and broader biomarker platform offer significant growth potential, though execution and adoption risks remain.
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.53 per share a year ago.
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
QTRX submits a 510(k) to the FDA for its multi-analyte blood test aimed at evaluating cognitive symptoms for possible Alzheimer's disease.
Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript
Quanterix Corporation ( QTRX ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Tom DeBourcy - Nephron Research LLC Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.
